Cell and Organ Transplantology. 2014; 2(1):53-55.
Change of the pattern of management of the kidney transplant patients with terminal stage of chronic renal failure
Salutin R. V.
Coordinating Centre of Transplantation for Organs, Tissue and Cells, Ministry of Health of Ukraine, Kyiv, Ukraine
The review presents results of clinical use of mTOR inhibitors, in particular, everolimus, in immunosuppressive therapy regimens. It has been established that immunosuppressive therapy regimens including mTOR inhibitors are preferred in patients with high and moderate risk of graft loss.
The analysis of the clinical use of mTOR inhibitors has provided evidence of the comparative incidence rate of wound complications and terms of surgical wound healing in the treatment with everolimus and the routine therapy.
Results of clinical trials have evidenced that minimization of therapy with calcineurin inhibitors and switching patients to everolimus allows for improvement of remote results of the kidney transplantation both due to reduced risk of nephrotoxic effect of calcineurin inhibitors, and due to anti-tumour and antiviral effects.
Key words: kidney transplantation, everolimus, mTOR inhibitor, immunosuppressionFull Text PDF (eng) Full text PDF (ua)
|1. Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation. 2009; 87(suppl. 8):19–22.
|2. Campistol JM, Boletis IN, Dantal J, et al. Chronic allograft nephropathy — a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. Clin. Transplant. 2009; 23(3):769–777.
|3. Arias M, Serón D, Moreso F, et al. Chronic renal allograft damage: existing challenges. Transplantation. 2011; 91(9):4–25.
|4. Holdaas H, Bentdal O, Pfeffer P, et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin. Transplant. 2008; 22(3):366–371.
|5. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation. 2004; 78(9):1332–1340.
|6. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolatemofetil in de novo renal transplant recipients. Transplantation. 2004; 78(10):1532–1540.
|7. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005; 80(2):244–252.
|8. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation. 2009; 87(2):157–163.
|9. Tedesco-Silva HJr, Vitko S, Pascual J, et al. 12-month safety and efficacy of Everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl. Int. 2007; 20(1):26–27.
Salutin RV. Change of the pattern of management of the kidney transplant patients with terminal stage of chronic renal failure. Cell and Organ Transplantology. 2014; 2(1):53-55. doi: 10.22494/COT.v2i1.40